Objectives. To investigate characteristics of data reported in US medical cannabis registries across states. Methods. Data included 2021 medical cannabis registry reports from 34 states, Puerto Rico, and the District of Columbia (hereafter, states) with active medical cannabis programs. The data from the reports were manually coded into domains and subcategories, including information related to patients (e.g., number, demographics), authorizing clinicians, sales (e.g., content, revenue), license tracking, and health and safety outcomes. Results. Among 36 states, 97% reported total patient number and 75% reported number of authorizing clinicians. Least reported subcategories included patient race/ethnicity (8%), adverse events (11%), therapeutic benefits (6%), and product recalls (6%). States that recently legalized medical cannabis (2013-2018) reported a higher number of subcategories overall, with a median of 11 versus 8 for early adopting states (1996-2012). More medical-use states reported data on authorizing clinicians compared with nonmedical adult-use states but were otherwise similar. Conclusions. Medical cannabis state registries generally reported data on consumers, clinicians, and sales rather than health and safety outcomes. More comprehensive and uniform medical cannabis public health surveillance is needed. (Am J Public Health. 2024;114(S8):S685-S693. https://doi.org/10.2105/AJPH.2024.307728).

中文翻译：

---

美国医用大麻患者州登记报告中的数据质量。


目标。调查美国各州医用大麻登记处报告的数据特征。方法。数据包括来自 34 个州、波多黎各和哥伦比亚特区（以下简称各州）的 2021 年医用大麻登记报告，这些州有积极的医用大麻计划。报告中的数据被手动编码到域和子类别中，包括与患者相关的信息（例如，数量、人口统计）、授权临床医生、销售（例如，内容、收入）、许可证跟踪以及健康和安全结果。结果。在 36 个州中，97% 报告了患者总数，75% 报告了授权临床医生的数量。报告最少的子类别包括患者种族/民族 （8%）、不良事件 （11%）、治疗益处 （6%） 和产品召回 （6%）。最近将医用大麻合法化的州（2013-2018年）报告的子类别总体数量更多，中位数为11个，而早期采用的州（1996-2012年）的子类别为8个。与非医疗成人使用州相比，更多的医疗使用州报告了授权临床医生的数据，但其他方面相似。结论。医用大麻各州登记处通常报告消费者、临床医生和销售的数据，而不是健康和安全结果。需要更全面和统一的医用大麻公共卫生监测。（美国公共卫生杂志，2024 年;114（S8）：S685-S693。https://doi.org/10.2105/AJPH.2024.307728）。